MiraLAX travel-size SKU approved
This article was originally published in The Tan Sheet
Executive Summary
FDA approves a supplemental new drug application for NeatPAX, a travel-size carton with 10 powder packets of MiraLAX (polyethylene glycol). The SNDA was submitted by Schering-Plough in April 2009, before its acquisition by Merck closed. FDA's May 5 1letter to the firm approves additional labeling for the laxative, including the statement "Sugar Free" for all stock-keeping units. Perrigo's launch of generic polyethylene glycol in 2009 has put pressure on Merck to innovate with MiraLAX or continue losing market share (2"The Tan Sheet" Nov. 9, 2009)
You may also be interested in...
Perrigo Strives To Stand Out Against Incoming Private Label Competition
Even as Perrigo products face the prospect of increasingly crowded segments, the company likes where it stands among private label competition
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.